Evidence map›Paper›PMID 39574390›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2024

Expert consensus on antimicrobial resistance research priorities to focus development and implementation of antibacterial vaccines and monoclonal antibodies.

Nasreen Hassoun-Kheir, Mariana Guedes, Fabiana Arieti, Maria Diletta Pezzani, Beryl Primrose Gladstone, Julie V Robotham, Koen B Pouwels, Rhys Kingston, Yehuda Carmeli, Alessandro Cassini and 15 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Epidemiology and risk factors ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Article
  4. Epidemiological characteristics of antimicrobial use in Primary Care in Spain: a nationwide study.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025
    Observational
  5. 'Antimicrobial resistance is invisible. I am not.'Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Nasreen Hassoun-KheirInfection Control Program, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center, Geneva, Switzerland.
Mariana GuedesInstituto de Biomedicina de Sevilla (IBiS), Infectious Diseases and Microbiology Division, Hospital Universitario Virgen Macarena, Department of Medicine, University of Sevilla/CSIC, Sevilla, Spain.
Fabiana ArietiInfectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Maria Diletta PezzaniInfectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Beryl Primrose GladstoneDZIF-Clinical Research Unit, Infectious Diseases, Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
Julie V RobothamHCAI, Fungal, AMR, AMU & Sepsis Division, UK Health Security Agency, London, United Kingdom.
Koen B PouwelsHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Rhys KingstonHCAI, Fungal, AMR, AMU & Sepsis Division, UK Health Security Agency, London, United Kingdom.
Yehuda CarmeliNational Institute for Antibiotic Resistance and Infection Control, Ministry of Health, Tel Aviv; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Alessandro CassiniInfectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland and Public Health Department, Canton of Vaud, Lausanne, Switzerland.
Michele CecchiniHead of Public Health, Health Division, OECD (Organisation for Economic Co-operation and Development), Paris, France.
Francis DrobniewskiDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Isabel FrostAstraZeneca, Eastbrook House, Cambridge, United Kingdom.
Jeroen GeurtsenBacterial Vaccines Research & Early Development, Janssen Vaccines & Prevention B.V., Leiden, the Netherlands.
Andreas KronenbergSwiss Centre for Antibiotic Resistance, Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
Mila Nu Nu HtayDepartment of Community Medicine, Faculty of Medicine, Manipal University College Malaysia, Melaka, Malaysia.
Mical PaulInfectious Diseases Institute, Rambam Health Care Campus; Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Nuno Rocha-PereiraDepartment of Medicine, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.
Jesús Rodríguez-BañoCIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Luigia ScudellerResearch and Innovation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Andrew J StewardsonDepartment of Infectious Diseases, The Alfred Hospital and School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
Evelina TacconelliInfectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Stephan HarbarthInfection Control Program, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center, Geneva, Switzerland.
Venanzio VellaGSK, Siena, Italy.
Marlieke Ea de KrakerInfection Control Program, Geneva University Hospitals and Faculty of Medicine, WHO Collaborating Center, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To reduce antimicrobial resistance (AMR), pathogen-specific AMR burden data are crucial to guide target selection for research and development of vaccines and monoclonal antibodies (mAbs). We identified knowledge gaps through previously conducted systematic reviews, which informed a Delphi expert consultation on future AMR research priorities and harmonisation strategies to support data-driven decision-making. Consensus (≥80% agreement) on importance and feasibility of research topics was achieved in two rounds, involving 24 of 39 and 19 of 24 invited experts, respectively. Priority pathogens and resistance profiles for future research were identified: third generation cephalosporin-resistant

Indexed as

Anti-Bacterial AgentsAntibodies, MonoclonalBacterial VaccinesDelphi TechniqueDrug Resistance, BacterialEuropeHumansKlebsiella pneumoniaeResearchAnti-Bacterial AgentsAntibodies, MonoclonalBacterial VaccinesAntimicrobial resistanceDelphiEuropegapsmonoclonal antibodiespolicyresearch priorityvaccines

Identifiers

PMID39574390
PMCPMC11583311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.